pone.0262198.s002.pdf (23.07 kB)
CONSORT diagram for the biomarker analyses in the AVANT trial.
journal contribution
posted on 2021-12-31, 18:45 authored by Anneleen Daemen, Akshata R. Udyavar, Thomas Sandmann, Congfen Li, Linda J. W. Bosch, William O’Gorman, Yijin Li, Amelia Au-Yeung, Chikara Takahashi, Omar Kabbarah, Richard Bourgon, Priti Hegde, Carlos Bais, Meghna Das Thakur(PDF)
History
Usage metrics
Categories
Keywords
year survival ratetargeted treatment evaluationprovides scientific rationaleincluded 1062 patientsconsensus molecular subtypescms2 tumor cellsbiomarker defined subpopulationspropagates stage iidisease &# 8217adjuvant stage iivalidation cohort gse39582immune &# 8212high granzyme bdisease specific roleaccurately capture highsignificant prognostic impactcell independent fashioncancer genome atlasalternative gzmb sourceperformed expression profilingrisk crc patientsindependent cohortstage iiimetastatic diseasetranscriptomic profilingspecific implicationsimmune componentcell linesrisk stratificationrisk crcrisk classificationresectable highimprove highfuture highxlink ">work furthersunderlying biologystill needretrospective analysisrelated deathsprospective threeprognostic signatureprognostic biologyleading causelarge datasetfound gzmbendogenously expressedeffector genesclinically validatedalthough robust
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC